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Abstract
Background: Aged polymedicated patients are particularly vulnerable for drug-related problems. A medication
review aims to optimize the medication use of patients and improve health outcomes. In this study, the effect of a
pharmacist-led medication use review is investigated for polymedicated ambulatory older patients with the aim of
implementing this pharmaceutical care intervention across Belgium.
Methods: This article describes the study protocol of the SIMENON study and reports the results of the
feasibility study, which aimed to test and optimize this study protocol. In the SIMENON intervention study,
75 Belgian community pharmacies each recruit 12 patients for a medication use review. For each patient,
the identified drug-related problems and subsequent interventions are registered using the PharmDISC
classification. In a subset of Dutch speaking patients, a pretest-posttest single group design is used to
measure the impact of this review on patient related outcomes using questionnaires. The main outcome of
the study is the type and number of drug-related problems and related interventions. A second outcome is
the impact of the medication use review on adherence, objectively measured with dispensing data.
Evolution in medication related quality of life is another outcome, measured with the Living with Medicines
Questionnaire version 3. Other patient reported outcomes include adherence, self-management, patient
satisfaction, fall incidents and use of emergency healthcare services.
Discussion: The findings of this study can provide data on the effectiveness of a medication use review in
the Belgian primary care setting. Furthermore, it will provide insights in which patients benefit most of this
intervention and therefore facilitate the implementation of medication review in Belgium.
Trial registration: ClinicalTrials.gov NCT03179722. Retrospectively registered 7 June 2017.
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Background
Aging populations, increase in chronic conditions and poly-
pharmacy are challenging healthcare systems worldwide. In
Belgium 17.9% of the population is aged 65 or more and at
least 19% of these patients are polymedicated [1]. Polymedi-
cation entails a risk for drug-related problems such as
non-adherence, drug interactions, adverse drug events and
hospitalizations [2]. Approximately 6 to 17% of acute hospi-
talizations in older patients are drug-related [3, 4]. In
Belgium 42.000 medication-related hospital admissions are
potentially preventable per year and could save 200 million
euros on a yearly basis [3–5].
A medication review is defined as “a structured evalu-
ation of a patient‘s medicines with the aim of optimizing
medicines use and improving health outcomes. This en-
tails detecting drug-related problems and recommending
interventions” [6]. Depending on the sources of informa-
tion used in the review, three types are distinguished: a
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basic, intermediate and advanced medication review [6].
Evidence exists that medication reviews can improve out-
comes such as adherence, appropriateness of prescribing
and emergency department contacts [7–9]. However the
evidence for an impact on the number of hospitalizations
is contradicting [7, 10].
The rising trend of medication review services in
healthcare is undeniable [11]. In countries such as
Australia, The Netherlands, The United Kingdom, Portugal,
Denmark and Switzerland medication reviews are a nation-
ally implemented reimbursed healthcare service [11]. Con-
trasting, the target population for an intermediate
medication review differs across countries and further
research should identify and target patients who would
benefit most of a review [8, 11].
The implementation of clinical services by pharmacists
in Belgium is also progressing. Since 2013, Belgian phar-
macists offer an advanced pharmaceutical care service for
new asthma patients. Moreover the federal government
has funded research on advanced medication reviews in
Belgian nursing homes [12]. Similarly, the Association of
Belgian Pharmacies has now taken initiatives to investigate
and implement intermediate medication reviews in pri-
mary care. For that purpose, a consortium with three Bel-
gian universities was set up to prepare and research the
implementation of this type of review, further referred to
as medication use review (MUR), in Belgian community
pharmacies.
In a first step, a feasibility study was conducted to test the
medication review six step process. The protocol, study ma-
terials and measures were optimised based on the feedback
of these participants. In a second step, the objective is to
Study the Impact of a Medication use EvaluatioN by the
cOmmuNity pharmacist (SIMENON study) in older poly-
medicated patients. Other members of the consortium will
focus on the added value of the standard application of the
GheOP3S tool1 (to evaluate appropriateness of prescribing)
and multidisciplinary case conferences during the medica-
tion review process [13]. Furthermore, thorough research
on the implementation of the service will be performed
using the RE-AIM model [14].
Methods/design
This study protocol is developed in line with SPIRIT rec-
ommendations for reporting clinical trial protocols [15].
Design, setting and study period
The SIMENON study is an intervention study with a
pretest-posttest single group design. The intervention is
performed by community pharmacists in the primary care
setting. Patients are followed over a period of 9 months.
Patient recruitment was planned from November 2016
until March 2017.
Pharmacy
Pharmacies in the three regions of Belgium (Flanders,
Brussels and Wallonia) could participate. Recruitment of
Belgian pharmacies occurred in the fall of 2016 via na-
tional and local pharmaceutical magazines. No inclusion
criteria were set but participation to the study workshop
(see 6. Education program) and a signed collaboration
agreement are required. Multiple pharmacists within one
pharmacy can perform medication reviews. Participation
comprises of performing twelve medicines use reviews,
registering the findings in a webtool and delivering medi-
cation refill records of the participating patients to the re-
search team.
Patient
Four patient inclusion criteria are set: patients should be
70 years or older, use five or more drugs chronically (both
prescription or non-prescription drugs) and live in the am-
bulatory setting. The age limit is set at 70 years. Given the
high population of patients aged 65 or older in Belgium
(approximately 2 million people), the researchers wanted to
further limit the size of the eligible study population. In line
with the aging population, several projects have been con-
ducted in primary care in Belgium which focused on pa-
tients aged 70 or more instead of 65 [16]. Finally, the
patient should obtain his medication from this pharmacy
on a regular basis. Patients can be Dutch or French speak-
ing. Dutch patients are also invited by their pharmacist to
participate to questionnaires for a pretest-posttest measure-
ment. Having a medication overview or the presence of a
carer or home nurse are no exclusion criteria since the pa-
tient remains involved in his medication use and/or medi-
cation experiences. Carers are allowed to accompany the
patient for the medication review.
Recruitment and consent
Based on the suggestions in the feasibility study (see 12.
Feasibility study), pharmacists are required to approach
each patient who meets the inclusion criteria on fixed
inclusion days to avoid selection bias. Upon informed
consent, Dutch speaking patients are proposed to fill out
questionnaires (see 9. Data collection). Patients can indi-
cate if they prefer to be contacted by the research team
either by phone, by e-mail or by letter to complete the
surveys.
Intervention
The intervention consists of a medication use review. In
this intermediate medication review both a patient inter-
view and medication refill records are used as information
sources to identify drug-related problems with a specific
focus on the medicines use of the patient [6]. Table 1 shows
the six components of the intervention which is based on
the Systematic Tool to Reduce Inappropriate Prescribing
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(STRIP) tool [17]. A checklist is available for participants to
ensure the quality of the medication reviews (available upon
request). The feasibility study confirmed the applicability of
this six step process and estimated a workload of 120 min
per review.
Upon patient recruitment, the patient is invited for a
pharmacotherapeutic anamnesis also referred to as a pa-
tient interview [17]. This interview can be either on ap-
pointment, during the next visit or immediately upon
consent. Patients are encouraged to bring their medication
(brown bag method) to this interview and list their
current medication. The anamnesis should preferably take
place in the pharmacy, if possible in a private area. In ex-
ceptional circumstances such as patient immobility, the
pharmacist can perform the anamnesis at the patients’
home. In preparation for the anamnesis, the pharmacist
consults the medication refill records to review adherence
and check drug interactions.
The aim of the patient interview itself is to gain insight
in the pharmacotherapy of the patient. Data on medica-
tion use, medication knowledge but also experiences are
gathered. Additional questions relate to non-medication
treatments, lifestyle, living situation, allergies, functional
status, hospitalization and fall incidents.
Subsequently, the pharmacist performs a pharmacother-
apeutic analysis to identify drug-related problems with par-
ticular focus on the medication use. Next, priorities are set
and interventions are prepared. The minimal output of a
medication review is a medication overview for the patient.
This overview comprises the current chronic medication
of the patient, both prescribed and non-prescribed. Aside
from the name of the medication, also the frequency and
time of intake and remarks are registered in this overview.
In the fifth step, the pharmacist and patient reconvene
to discuss and execute the interventions. The pharmacist
runs through the medication overview with the patient
and checks if everything is understandable for the patient.
It is recommended to perform this second consultation
within 2 weeks after the anamnesis. Finally, in the follow
up conversation the pharmacist investigates if the under-
taken actions were useful and investigates if new problems
have emerged or new interventions are required. If neces-
sary, the medication overview is updated. It is recom-
mended to perform this follow up a month after the
second patient-pharmacist conversation.
Although the medication use review is initiated by the
community pharmacist, collaboration with the general
practitioner (GP) is encouraged. For instance by informing
the GP before the anamnesis, by actively discussing the
pharmacotherapy of the patient during the analysis or by
sharing the medication overview of the patient. The feasi-
bility study uncovered there was no consensus on how the
general practitioner should be involved in the review
process. There was no support to organize interdisciplin-
ary case conferences for each patient, nor to inform the
GP before each review. Depending on the drug-related
problems that are discovered, discussion with the GP or
patient referral may be necessary.
Education program
The educational program for participating pharmacists
consists of five components: an information session, work-
shop, toolbox, documentation and an intervision session
(Table 2). All sessions are organized in fivefold across
Belgium. The feasibility study provided insights in the
training needs of pharmacists in Belgium and was used to
optimize this educational program.
In the first information session interested pharmacists are
informed about the aims of the SIMENON study, the pro-
cedure of a medicines use review and are given the oppor-
tunity to ask questions. In the subsequent obligatory
interactive workshop of 2 hours, participants are familiar-
ized with a MUR. The research team of KU Leuven demon-
strates a MUR using a simulation patient. Attention is
drawn to the drug-related problems that should be detected
and its classification (see 7. Outcomes) and to communica-
tion skills for patient and GP conversations.
The toolbox supports participants in the analysis phase
by providing background information and evidence-based
references and websites. The following six topics are ad-
dressed, based on the feedback in the feasibility study: geri-
atric patients and characteristics, drug interactions and side
effects, adherence, drug use including time of intake and a
written example of a medication review.
The following documentation is available for the com-
munity pharmacist: an overview of the steps of a medica-
tion review including a checklist, a letter for the GP with
study information and a referral letter. For the patients, an
information leaflet with informed consent form is foreseen
as well as a blank medication list and a brown bag. Finally,
an intervision moment is organized halfway in the project
Table 1 The six-step process of a medication review [17].
The time points of data collection for the SIMENON study are
indicated. Both the community pharmacists (CP) and the
researchers (R) collect data at different time points
Component Time
point
Data
collection
Medication
review
1 Patient recruitment T-1week R
2 Preparation CP
3 Patient interview T0 CP
4 Pharmacotherapeutic
analysis
5 Discussing medication list T2weeks CP
T3weeks R
6 Follow up T6weeks CP
T12weeks R
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for participants to exchange experiences, feedback and
tips and tricks for patient inclusions.
Outcomes
The main outcome of the study is the type and number of
drug-related problems and related interventions registered
by pharmacists using the validated PharmDISC2 classifica-
tion tool (a process measure) [18]. A second outcome is
the impact of the medication review on adherence, object-
ively measured with medication refill data. A third out-
come is the medication related quality of life, measured
with the Living with Medicines Questionnaire version 3
(LMQ) [19]. Other patient related outcomes are adherence,
self-management, patient satisfaction, use of emergency
healthcare services and fall incidents. These outcomes are
measured via the pre-post study design using patient
questionnaires.
Data collection
An overview of the data collection strategies is shown in
Table 3. Four types of quantitative data are collected:
drug-related problems and interventions, medication refill
records, patient questionnaires and descriptive pharmacist
information. If patients would withdraw consent, no add-
itional data is registered but existing data is preserved.
For each patient receiving a review, an online registration
form is completed by the pharmacist via a webtool (avail-
able upon request). Pharmacists are required to login to use
this webtool and only coded patient information can be
registered. Drug-related problems and interventions are
registered throughout the medication review process using
the PharmDISC classification system [18]. Permission was
given by the authors to translate and use the instrument.
Participating pharmacists are given a manual with explan-
ation and examples to ensure the quality of the classifica-
tion. Medication refill data is collected of all participants in
the study to estimate adherence before and after the medi-
cation review. Data is collected from 9 months before until
9 months after the review. Finally, all participating pharma-
cists are required to fill in a questionnaire related to phar-
macy and pharmacist characteristics.
The effectiveness of a medication use review is evaluated
using patient reported outcomes. Patients are surveyed at
three time points by the research team of KU Leuven
Table 2 Overview of the topics in the educational program of the SIMENON study
Education
program
Topic
Study
procedure
Background and evidence based
info
Communication skills and patient
inclusion
Multidisciplinary
collaboration
Information
session
X
Workshop X X X
Toolbox X
Documentation X X X
Intervision session X X X
Table 3 Overview of the data collected for the SIMENON study
Data
collection
A. Drug-related problems &
interventions
B. Adherence C. Questionnaires D. Descriptive pharmacist
information
Subject Patient Patient Patient Pharmacist
Collector Pharmacist Pharmacist Researcher Pharmacist
Sample size 900 patients 900 patients 140 patients 75 pharmacies
Method Questionnaire: webtool Medication refill
records
Questionnaire: by letter, by phone or
by e-mail
Questionnaire
Frequency Four times Once Three times Once
Timeframe During the medication review
process
• 9 months before
• 9 months after the
review
• 1 week before the review
• 3 weeks after the review
• 12 weeks after the review
Before start of the study
Content • Administrative and medical data
• DRPs and interventions
• Duration
• GP contacts
Medication refill
records
• Adherence
• Self-management
• Polypharmacy burden
• Satisfaction
• Demographic data
• Use of emergency healthcare services
• Fall incidents
• Pharmacy and Pharmacist
characteristics
• Pharmacist experiences
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(Table 4). Based on the preferences of the patient the ques-
tionnaires can be completed by e-mail, by phone or by mail.
These surveys allow an insight in patient experiences. Table
4 provides an overview of instruments and the time points
of data collection. Permission was given by all authors to
use the instruments. The ‘Living with Medicines Question-
naire’ and the ‘Patient Satisfaction with Pharmacist Services
Questionnaire’ were translated by the researchers in ac-
cordance with ISPOR guidelines [20].
Data management
Patient confidentially is ensured through patient coding
during data registration by the treating community
pharmacist. Data obtained from the questionnaires are also
coded by the researchers. The study database only contains
coded data. Data cleaning and analysis is performed by the
research group of KU Leuven. All parties of the consortium
have access to the final database as stated in the collabor-
ation agreement. Sharing of anonymized individual clinical
trial participant-level data is possible for research purposes
which are in line with the initial aim of data collection. Data
is disseminated through publication in peer reviewed inter-
national journals.
Data analysis
First, descriptive statistics will be used to characterize the
study population using demographic parameters, to give
an overview of drug-related problems, interventions and
level of implementation. Secondly, adherence will be cal-
culated using two methods for the analysis of refill data:
the medication possession ratio as well as proportion of
days covered. The impact will be measured by comparing
data before and after the intervention using appropriate
statistical tests for paired data. Subsequently the correl-
ation between objective measures for adherence (medica-
tion refill records) and subjective measures (PROMAS
score) will be investigated [21]). In addition, the results of
these adherence measures will be compared with the reg-
istered drug-related problems and interventions. This
provides insight in the number of (un)detected adherence
problems and the effectiveness of a medication review and
interventions to improve adherence.
Third, patient questionnaires will be scored in accord-
ance with the described methods of the original authors.
The impact of the intervention will be explored using
appropriate statistical tests for paired data. Subgroup
analysis will compare the baseline scores in the three
types of data collection (letter, phone or email) to ensure
the quality of the data.
A final analysis aims to identify patients with a high
risk of drug-related problems by investigating the impact
of variables on the number of drug-related problems de-
tected by pharmacists. These variables have been defined
a priori based on scientific research as well as patient
criteria for a medication review in countries abroad.
Both patient related factors, process factors and phar-
macy related factors will be explored. All analysis will be
performed using the statistical program SPSS. A per
protocol analysis and a listwise deletion will be applied.
Sample size
The study aims to approach 75 pharmacies in Belgium,
approximately half in Flanders and half in Wallonia.
Each pharmacy in turn includes 12 patients. This brings
the total number of participants to 900 (Table 5). The
primary aim of this study is to describe the type and
number of drug-related problems and related interven-
tions for each patient. In this way, the primary outcome
is a process measure. The secondary outcome is medica-
tion adherence. A systematic review by Hatah et al.
shows that both an intermediate and advanced medica-
tion review by community pharmacists significantly im-
proves adherence [7]. Provided that the pharmacist can
improve adherence using a medication review in half of
the patients with a low adherence (10% of all older pa-
tients) and a significance level of 5% and power of 80%,
a sample size of 746 patients is calculated [21, 22].
Table 4 Patient related outcome measures. Data is collected 1 week before the patient interview (T-1w), 3 weeks later (T3) and 12
weeks after the patient interview (T12w)
Subject Instrument Authors T-
1w
T3w T12w
Adherence Probabilistic Medication Adherence Scale (ProMAS) Kleppe et al. 2015 [21] X X
Self-management Patient Activation Measure (PAM) Hibbard et al. 2004 [22] X X
Polypharmacy burden Living with Medicines Questionnaire (LMQ) Krska et al. 2014 [23] X X X
Satisfaction Patient Satisfaction with Pharmacist Services Questionnaire (PSPSQ)
2.0
Sakharkar et al. 2015
[24]
X
Demographic data Living with Medicines Questionnaire (LMQ) Krska et al. 2014 [23] X X X
Use of emergency healthcare
services
/ X X
Fall incidents / X X
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Taking into account a drop-out rate and missing data (17%,
n = 154) a sample size of 900 participants is proposed.
For the patient reported outcomes using questionnaires,
all Dutch-speaking patients in the Flemish community
pharmacies (approximately 35) are approached. It is hy-
pothesized that 2/3 of patients who consent to a medica-
tion review also agree to complete the questionnaires.
Considering a drop-out rate of 50%, data should be avail-
able for 140 patients (Table 5). In this subset, the score on
the Living with Medicines Questionnaire is the main out-
come. However, since this instrument has not yet been
used in an older polymedicated population, no sample size
calculation can be performed.
Feasibility study
In preparation for the SIMENON study, a feasibility study
was conducted from March 2016 until September 2016.
The aim was to gather insights in the feasibility of the pro-
posed medication review six step process, the protocol of
the study (with specific attention to patient inclusion cri-
teria and recruitment) and the content of the educational
program. Using purposive sampling, six pharmacists partic-
ipated, both Dutch and French speaking from different re-
gions. Ethical approval was granted for this study in May
2016 by the Ethics committee of UZ/KU Leuven
(S58952 V3) and after that patient inclusion commenced.
In total 19 patients were recruited.
Using an iterative process with group discussions and
individual contacts, feedback of the participating pharma-
cists was incorporated in the design of the SIMENON
study. Specific feedback was given in relation to the edu-
cational program and more specifically the need for back-
ground information. No significant adjustments were
required for the medication review process itself. Patient
recruitment proved to be the most important hurdle. The
shared decision was made to work with fixed inclusion
days in the pharmacy to minimize selection bias. Finally,
the different participants all had different approaches to
communicate with the treating physician ranging from no
contact, contact before the medication review and contact
if necessary in the fourth step of the review process. None
of the participants supported the proposal of a multidis-
ciplinary case conference for each patient since the pri-
mary focus of the review was medication use rather than
appropriateness of prescribing.
Study registration
This study protocol has been reviewed and approved by the
ethics committee UZ/KU Leuven (number S59676 V3) in
November 2016. The SIMENON study has been retro-
spectively registered in June 2017 in the trial database avail-
able at www.clinicaltrials.gov (NCT03179722).
Trial status
Study recruitment commenced on 5 December 2016. In
March 2017, the aimed number of included patients was
not attained. Therefore, the decision was made to pro-
long patient inclusions until the end of May and post-
pone study finalization until March 2018. The final
dataset should be collected by October 2018.
Discussion
In this study intermediate medication reviews are con-
ducted and evaluated. The main outcome of the study is
the type and number of drug-related problems and related
interventions. A second outcome is the impact of the
medication use review on adherence, objectively measured
with dispensing data. A third outcome is the impact on
the medication related quality of life, measured with the
Living with Medicines Questionnaire. This study is in line
with similar pharmacist-led interventions worldwide. In
Europe alone, initiatives on intermediate medication re-
view have been performed in at least 11 countries [11].
The findings and experiences from these countries have
been incorporated in this study protocol.
For one, the target population consists of aged, polyme-
dicated patients. These criteria are in line with the recom-
mended target population for clinical pharmacy services
in the Netherlands and UK [23, 24]. This research will
provide further insights in the patient population who
benefits most of a medication review. For this purpose,
also the assistance patients receive in their medicines use,
both by professionals, carers and devices such as pill boxes
are registered. Secondly attention is drawn to a random
patient inclusion in the pharmacy to avoid selection bias.
Furthermore, there is an obligatory follow up consultation.
In contrast to similar studies, this study not only investi-
gates DRPs and interventions but also focusses on the ac-
tual implementation of the interventions [25]. Unlike the
study of Holland et al. 2005, this intervention is conducted
by trained local community pharmacists with whom the
patient has a therapeutic relationship [26]. This real-life
context could facilitate the implementation in a later
phase. In addition, the feasibility study provided insight in
training needs of participants and the feasibility of the
study protocol. Another strength of this study is that the
outcomes allow insight in both the clinical impact by de-
tecting and resolving drug-related problems as well as the
patient perspective on the medication use, medicines ex-
periences and the perceptions on the new service. The
Table 5 Sample size
Sample size Medication
review
Questionnaires
Number of Belgian community
pharmacies
75 35
Number of participating patients per
pharmacy
12 4
Total number of participating patients 900 140
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systematic review by Loh et al. 2016 has demonstrated
there is no evidence that a MR significantly improves
overall health related quality of life, possibly due to the
generic nature of the instruments used. Therefore, this
study is the first to use a medication specific tool, the Liv-
ing with Medicines Questionnaire, to map the medication
related quality of life [19, 27]. In addition, the adherence
outcome is both objectively measured as well as using
subjective patient questionnaires. A final strength of the
study is that it is performed by a consortium of three
Belgium universities and the national pharmacy associ-
ation. This allows a combination of research perspectives.
This study also has several limitations. For one this
study is no randomized controlled trial. Although there is
no control group, the study provides a detailed description
of the drug-related problems and pharmacy interventions.
Since many other countries have implemented medication
review in the past, this study is on that aspect not very in-
novative, yet essential since the healthcare system differs
across countries and subsequently not all findings are
transferable. By using voluntary participation of pharma-
cists, this creates participating bias. Although the patients
should be randomly chosen, it is expected that the most
motivated patients who are open to this intervention are
included in the study. This also limits the generalizability
of the findings. Moreover, the patient follow up is limited
to 3 months. Literature suggests this may be rather short
to detect an impact on the quality of life [25].
Another limitation of this medication review is that
collaborative practice with the general practitioner is not
required. Additional input from the GP would indisput-
ably be of added value. However, only a limited amount
of initiatives (3/11) in Europe organize case conferences
during an intermediate medication review [11]. More-
over, the findings of the feasibility study showed reluc-
tance. Notwithstanding GP collaboration is registered in
the webtool and allows subgroup analysis of patients for
which multidisciplinary contacts were made.
In conclusion, this study contributes to the evolv-
ing role of community pharmacists in Belgium. The
findings of this study could provide valuable insights
on the drug-related problems that older polymedicated
patients experience in Belgium, the patients who would
benefit most of a medication review and the value of the
community pharmacist in resolving these problems. There-
fore, the SIMENON study could significantly support the
implementation of medication reviews in Belgium.
Endnotes
1GheOP3S tool: Ghent Older People’s Prescriptions
community Pharmacy Screening tool
2PharmDISC: Pharmacist’s Documentation of Inter-
ventions in Seamless Care
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